12 Participants NeededMy employer runs this trial

Quercetin for Dyskeratosis Congenita

SL
MT
Overseen ByMonica Trapp, BSN, RN, TCTCN
Age: Any Age
Sex: Any
Trial Phase: Phase 1
Sponsor: Children's Hospital Medical Center, Cincinnati
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial explores the safety of quercetin, a vitamin-like substance, for individuals with Dyskeratosis congenita (DC) or telomere biology disorders (TBD). These rare conditions can affect the skin, nails, and blood. Participants will take quercetin orally twice a day. The trial seeks individuals diagnosed with DC or TBD who can take medication by mouth. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new treatment.

Will I have to stop taking my current medications?

You may need to stop taking certain medications. If you are on androgen therapy, digoxin, or fluoroquinolone and cannot stop for medical reasons, you may not be eligible to participate.

Is there any evidence suggesting that quercetin is likely to be safe for humans?

Research has shown that quercetin is generally safe for people. One study found that individuals with conditions similar to Dyskeratosis congenita (DC) tolerated quercetin well at all tested doses. Other studies in adults suggest that taking up to 1,000 mg of quercetin daily for 12 weeks is likely safe. No evidence indicates that quercetin is seriously toxic or causes cancer. While more research is needed for people with DC, these early findings offer some reassurance about quercetin's safety.12345

Why do researchers think this study treatment might be promising?

Unlike the standard treatments for Dyskeratosis Congenita, which often focus on managing symptoms with therapies like androgens, steroids, or bone marrow transplantation, Quercetin offers a novel approach. Quercetin is a plant-derived compound known for its antioxidant properties, which may target the cellular stress and damage linked to this genetic disorder. Researchers are excited about its potential to provide a more direct and less invasive treatment option by addressing underlying cellular issues rather than just alleviating symptoms. This could mean a significant improvement in quality of life for patients with fewer side effects compared to more aggressive treatments.

What evidence suggests that quercetin might be an effective treatment for Dyskeratosis congenita?

Studies have shown that quercetin, a natural compound in many fruits and vegetables, may help with issues related to telomeres. Telomeres are parts of DNA that influence aging and cell health. Research suggests that quercetin can lengthen telomeres, with one study noting a significant increase after supplementation. Quercetin has also been studied for its ability to reduce senescent cells, which are old cells that have stopped dividing and can cause harm. This suggests quercetin might improve cell health. Although limited studies exist on quercetin specifically for Dyskeratosis congenita, a rare condition affecting telomeres, these findings offer a hopeful starting point. Participants in this trial will receive quercetin to evaluate its effects on Dyskeratosis congenita.12367

Who Is on the Research Team?

PM

Parinda Mehta, MD

Principal Investigator

Children's Hospital Medical Center, Cincinnati

Are You a Good Fit for This Trial?

This trial is for people diagnosed with Dyskeratosis congenita (DC) or other telomere biology disorders. Specific inclusion and exclusion criteria are not listed, but participants must have one of these rare conditions.

Inclusion Criteria

Diagnosis of DC/TBD deficiency defined by age adjusted mean-telomere length of <1 percentile in all tested peripheral blood cells such as granulocytes, lymphocytes, B-cells, naïve T-cells, memory T-cells, and NK cells
Able to take medication orally
I am at least 2 years old.
See 1 more

Exclusion Criteria

Participating in another therapeutic study for DC/TBD
Total bilirubin >3 mg/dl and/or SGPT >300 at time of enrollment unless elevation thought to be related to DC/TBD
Patients who are pregnant or breastfeeding or at risk of pregnancy and unable to use acceptable methods of birth control during the length of the study
See 9 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive quercetin treatment for Dyskeratosis Congenita/Telomere Biology Disorders

24 weeks
Regular visits for monitoring treatment-emergent adverse events

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • Quercetin

Trial Overview

The study is testing the safety of quercetin, a vitamin-like substance, in individuals with DC or telomere biology disorders. All participants will receive quercetin to see how well it is tolerated.

How Is the Trial Designed?

1

Treatment groups

Experimental Treatment

Group I: QuercetinExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Children's Hospital Medical Center, Cincinnati

Lead Sponsor

Trials
844
Recruited
6,566,000+

Citations

Quercetin Dyskeratosis Congenita (DC)/Telomere Biology ...

It identifies the role of the intervention that participants receive. Types of arms include experimental arm, active comparator arm, placebo ...

Dyskeratosis Congenita Links Telomere Attrition to Age ... - PMC

Senolytics decrease senescent cells in humans: preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease ...

Quercetin Dyskeratosis Congenita (DC)/Telomere Biology ...

This study will enroll approximately 12 patients with DC/TBD who will be treated with quercetin for 24 weeks.

Quercetin Intake and Absolute Telomere Length in Patients ...

Quercetin supplementation was associated with a significant increase in mean TL (odds ratio ≥ 2.44; p < 0.05) with a strengthened association after full ...

Dyskeratosis congenita: natural history of the disease ...

Six patients died, the median age was 13 years. As of November 2022, eight patients were still alive, with a median age of 18 years [range, 6–32 years].

Risk assessment of quercetin dihydrate and rutin in food ...

In rats, the highest quercetin levels were found in lung, testis and kidney the safety data were not shown. The results of any self-reported ...

Safety Data Sheet: Quercetin

Uses advised against: Do not use for products which come into contact with foodstuffs. Do not use for private purposes (household). Food, drink and animal ...